Cognition Therapeutics Inc.
CogRx is a clinical-stage pharmaceutical company developing novel drugs that work through a completely new mechanism to treat or prevent Alzheimer's disease.
- Stage Product In Development
- Industry Biotechnology
- Location Pittsburgh, PA, USA
- Currency USD
- Founded August 2007
- Employees 8
- Incorporation Type C-corp
- Website CogRx.com
Company Summary
Cognition Therapeutics (CogRx) is a clinical-stage small molecule therapeutics company focused on the discovery and development of novel drugs for neurodegenerative diseases. CogRx has discovered first-in-class therapeutics that selectively block soluble Aβ oligomers from causing cognitive decline. CogRx’s compounds work through a new neuronal Aβ oligomer receptor complex to reverse memory loss in Alzheimer's disease models.
Team
-
Franz HeftiFounder and Board Director
-
Susan CatalanoChief Science Officer
Scientific leadership positions at Roche, Rigel and Acumen
Discovered Rigel’s Aurora kinase inhibitor R763
17 yrs pharmaceutical discovery experience -
Hank SaffersteinVP
Worldwide Licensing and Marketing positions, Bristol-Myers Squibb
Head of Corporate Development (3 early-stage biotechnology companies)
19 yrs pharmaceutical experience
Executive in Residence, Pittsburgh Life Science Greenhouse -
Gilbert RishtonChemistry Advisor
Founding medicinal chemist for Amgen’s small molecule chemistry effort
Chemistry manager for Amgen’s Sensipar development program (preclinical and clinical)
16 yrs pharmaceutical discovery experience -
President and CEO
President & CEO at Chimerix, Alteon, Biocyte
Founder and VP at The Liposome Company
Experience in venture capital, consulting (McKinsey) and investment banking
Advisors
-
Kate Shay at Duane MorrisLawyerUnconfirmedDonnelly and BolandAccountantUnconfirmed
Previous Investors
-
Pittsburgh Life Sciences Greenhouse, Innovation WorksUnconfirmedOgden Capital, M5 InvestUnconfirmedGolden Seeds, Tech Coast AngelsUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.